Company intelligence / Profile preview

Jenthera Therapeutics

Montreal/Saint-Laurent, Quebec, Canadajenthera.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Jenthera’s preclinical data show complete eradication of targeted tumors at low doses in both their CAR-T and KRAS programs. Their technology enables high-frequency homology-directed repair and targeted systemic delivery to solid tumors with strong safety profiles regarding off-target effects and immunogenicity. They are currently seeking Series A investment and partnerships to advance toward the clinic.

Therapeutic areas: OncologyCardiovascular
Modalities: CRISPR-Cas gene editing (direct protein delivery)Ribonucleoprotein complexesProtein-based drugs
Industry: Biotech

Drug pipeline

1 asset

Jenthera viral gene editing program

Preclinical

Partnerships

Future Fields – collaboration on sustainable mass production of novel proteins using EntoEngine™ biomanufacturing platform for scalable recombinant therapeutic production.

Beyond the preview

Go deeper on Jenthera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jenthera Therapeutics.

Explore the full profile